thioctic acid has been researched along with Diabetes Mellitus in 59 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 7.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 3.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| "This is a prospective parallel, randomized, double-blind, placebo-controlled trial to study the effects of α lipoic acid in combination with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN." | 3.11 | Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial. ( Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y, 2022) |
| "Its efficacy in neuropathic pain in diabetes mellitus still lacks enough research." | 3.11 | The 8-Week Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) as an Add-on Therapy in the Treatment of Symptomatic Diabetic Peripheral Polyneuropathy. ( Dziemidok, P; Gorczyca-Siudak, D, 2022) |
| " Our meta-analysis is aimed at evaluating the effects of oral-administered ALA versus a placebo in patients with DSPN and determining the optimal dosage for this treatment." | 3.01 | Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. ( Chen, C; Hsieh, RY; Huang, IC; Sung, JY, 2023) |
| " It is widely accepted that diabetes impairs endothelial nitric oxide synthase (eNOS) activity and increases the production of ROS, thus resulting in diminished NO bioavailability and increased oxidative stress." | 2.52 | Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. ( Ghibu, S; Muresan, A; Rochette, L; Vergely, C, 2015) |
| "Diabetic cataracts are caused by an elevation of polyols within the lens of the eye catalyzed by the enzyme aldose reductase." | 2.41 | Natural therapies for ocular disorders, part two: cataracts and glaucoma. ( Head, KA, 2001) |
| "The incidence of NIDDM is highest in economically developed nations, particularly the U." | 2.41 | Use of antioxidant nutrients in the prevention and treatment of type 2 diabetes. ( McDonald, RB; Ruhe, RC, 2001) |
| "ALA integrative administration at a low dosage as 400 mg daily improved the metabolic impairment of all PCOS patients especially in those PCOS with familiar diabetes who have a higher grade of risk of NAFLD and predisposition to diabetes." | 1.48 | Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. ( Della Casa, D; Despini, G; Genazzani, AD; Manzo, A; Napolitano, A; Prati, A; Shefer, K; Simoncini, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (16.95) | 18.7374 |
| 1990's | 6 (10.17) | 18.2507 |
| 2000's | 14 (23.73) | 29.6817 |
| 2010's | 13 (22.03) | 24.3611 |
| 2020's | 16 (27.12) | 2.80 |
| Authors | Studies |
|---|---|
| Esin, RG | 1 |
| Khairullin, IK | 1 |
| Esin, OR | 1 |
| Li, Q | 1 |
| Liu, K | 1 |
| Jiang, T | 1 |
| Ren, S | 1 |
| Kang, Y | 1 |
| Li, W | 1 |
| Yao, H | 1 |
| Yang, X | 1 |
| Dai, H | 1 |
| Chen, Z | 1 |
| Xing, Q | 1 |
| Yang, Y | 2 |
| Liu, YY | 1 |
| Hu, L | 1 |
| Zhang, R | 1 |
| Du, JL | 1 |
| Abdel Hamid, DZ | 1 |
| Nienaa, YA | 1 |
| Mostafa, TM | 1 |
| Jiao, S | 1 |
| Dong, Y | 2 |
| Chang, X | 1 |
| Wu, Y | 1 |
| Li, H | 1 |
| Lekhanya, PK | 1 |
| Mokgalaboni, K | 1 |
| Zhang, T | 1 |
| Zhang, D | 1 |
| Zhang, Z | 1 |
| Tian, J | 1 |
| An, J | 1 |
| Zhang, W | 1 |
| Ben, Y | 1 |
| Gorczyca-Siudak, D | 1 |
| Dziemidok, P | 1 |
| Vasilios, AG | 1 |
| George, S | 1 |
| Charalambos, K | 1 |
| Valasia, A | 1 |
| Jermendy, G | 1 |
| Rokszin, G | 1 |
| Fábián, I | 1 |
| Kempler, P | 1 |
| Wittmann, I | 1 |
| Hsieh, RY | 1 |
| Huang, IC | 1 |
| Chen, C | 1 |
| Sung, JY | 1 |
| Srivastava, A | 1 |
| Gupta, V | 1 |
| Maheshwari, PK | 1 |
| Cure, E | 1 |
| Cumhur Cure, M | 1 |
| Jeffrey, S | 1 |
| Samraj, PI | 1 |
| Raj, BS | 1 |
| Frank, J | 1 |
| Kisters, K | 1 |
| Stirban, OA | 1 |
| Obeid, R | 1 |
| Lorkowski, S | 1 |
| Wallert, M | 1 |
| Egert, S | 1 |
| Podszun, MC | 1 |
| Eckert, GP | 1 |
| Pettersen, JA | 1 |
| Venturelli, S | 1 |
| Classen, HG | 1 |
| Golombek, J | 1 |
| Sovrani, V | 1 |
| Bobermin, LD | 1 |
| Schmitz, I | 1 |
| Leipnitz, G | 1 |
| Quincozes-Santos, A | 1 |
| Genazzani, AD | 1 |
| Shefer, K | 1 |
| Della Casa, D | 1 |
| Prati, A | 1 |
| Napolitano, A | 1 |
| Manzo, A | 1 |
| Despini, G | 1 |
| Simoncini, T | 1 |
| Zhang, GW | 1 |
| Liu, W | 1 |
| Shang, XJ | 1 |
| Papanas, N | 1 |
| Ziegler, D | 1 |
| Coletta, C | 1 |
| Módis, K | 1 |
| Szczesny, B | 1 |
| Brunyánszki, A | 1 |
| Oláh, G | 1 |
| Rios, EC | 1 |
| Yanagi, K | 1 |
| Ahmad, A | 1 |
| Papapetropoulos, A | 1 |
| Szabo, C | 1 |
| Lo, MC | 1 |
| Chen, MH | 1 |
| Lee, WS | 1 |
| Lu, CI | 1 |
| Chang, CR | 1 |
| Kao, SH | 1 |
| Lee, HM | 1 |
| Rochette, L | 2 |
| Ghibu, S | 3 |
| Muresan, A | 2 |
| Vergely, C | 3 |
| Gao, S | 1 |
| Park, BM | 1 |
| Cha, SA | 1 |
| Bae, UJ | 1 |
| Park, BH | 1 |
| Park, WH | 1 |
| Kim, SH | 1 |
| Richard, C | 2 |
| Delemasure, S | 1 |
| Mogosan, C | 1 |
| Singh, U | 1 |
| Jialal, I | 1 |
| Golbidi, S | 2 |
| Laher, I | 2 |
| Ebadi, SA | 1 |
| Volchegorskiĭ, IA | 1 |
| Rassokhina, LM | 1 |
| Koliadich, MI | 1 |
| Alekseev, MI | 1 |
| DU, SC | 1 |
| Ge, QM | 1 |
| Lin, N | 1 |
| Su, Q | 1 |
| Wang, W | 1 |
| Liu, Y | 1 |
| Guo, T | 1 |
| Chen, P | 1 |
| Ma, K | 1 |
| Zhou, C | 1 |
| Zeller, M | 1 |
| Cottin, Y | 1 |
| Obrosova, IG | 1 |
| Fathallah, L | 1 |
| Liu, E | 1 |
| Nourooz-Zadeh, J | 1 |
| Henriksen, EJ | 1 |
| Saengsirisuwan, V | 1 |
| FLINN, LB | 1 |
| D'ALONZO, CA | 1 |
| SCHREIBER, FK | 1 |
| SLADKI, E | 1 |
| MALDYK, H | 1 |
| PRUSINSKI, A | 1 |
| Naruse, K | 1 |
| Nakamura, J | 1 |
| Demiot, C | 1 |
| Fromy, B | 1 |
| Saumet, JL | 1 |
| Sigaudo-Roussel, D | 1 |
| Elliott, RB | 1 |
| Cakatay, U | 1 |
| Kayali, R | 1 |
| Coleman, MD | 1 |
| Rimmer, GS | 1 |
| Haenen, GR | 1 |
| McCarty, MF | 2 |
| Rubin, EJ | 1 |
| Schleicher, ED | 1 |
| Wagner, E | 1 |
| Nerlich, AG | 1 |
| Chevion, S | 1 |
| Hofmann, M | 1 |
| Ziegler, R | 1 |
| Chevion, M | 1 |
| Nawroth, PP | 1 |
| Kilic, F | 1 |
| Handelman, GJ | 1 |
| Traber, K | 1 |
| Tsang, K | 1 |
| Packer, L | 3 |
| Trevithick, JR | 1 |
| Konrad, T | 1 |
| Vicini, P | 1 |
| Kusterer, K | 1 |
| Höflich, A | 1 |
| Assadkhani, A | 1 |
| Böhles, HJ | 1 |
| Sewell, A | 1 |
| Tritschler, HJ | 1 |
| Cobelli, C | 1 |
| Usadel, KH | 1 |
| Stockklauser-Färber, K | 1 |
| Ballhausen, T | 1 |
| Laufer, A | 1 |
| Rösen, P | 1 |
| Head, KA | 1 |
| Ruhe, RC | 1 |
| McDonald, RB | 1 |
| Kraemer, K | 1 |
| Rimbach, G | 1 |
| Skoromets, AA | 1 |
| Barantsevich, ER | 1 |
| Petrova, NN | 1 |
| Mel'nikova, EV | 1 |
| Suzuki, YJ | 1 |
| Tsuchiya, M | 1 |
| Lesnichiĭ, AV | 1 |
| Dabski, H | 1 |
| Ivkov, VG | 1 |
| Klein, W | 1 |
| Sauer, H | 1 |
| Böninger, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading[NCT02439879] | Phase 4 | 45 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.[NCT01221350] | 55 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total symptoms score is a summation of presence, severity, and duration of the four main positive neuropathic sensory symptoms: lancinating/stabbing pain, burning pain, paresthesia, and asleep numbness (NCT02439879)
Timeframe: 20 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alpha Lipoic Acid Treatment | 2.5 |
| Alpha Lipoic Acid Withdrawal | 3.1 |
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products (NCT01221350)
Timeframe: Baseline
| Intervention | nmol/mg (Mean) |
|---|---|
| Lipoic Acid | 7.5 |
| Placebo | 10.12 |
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products. (NCT01221350)
Timeframe: 60 days
| Intervention | nmol/mg (Mean) |
|---|---|
| Lipoic Acid | 3.24 |
| Placebo | 4.21 |
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: Baseline
| Intervention | Eosinophil percentage in sputum cells (Mean) |
|---|---|
| Lipoic Acid | 12.88 |
| Placebo | 6.10 |
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: 60 days
| Intervention | Eosinophil percentage in sputum cells (Mean) |
|---|---|
| Lipoic Acid | 6.39 |
| Placebo | 5.68 |
Induced sputum of GSH and GSSG levels at baseline. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: Baseline
| Intervention | ratio (Mean) |
|---|---|
| Lipoic Acid | 81.42 |
| Placebo | 35.77 |
Change in the induced sputum of antioxidant parameters GSH and GSSG levels after 60 days of treatment. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: 60 days
| Intervention | ratio (Mean) |
|---|---|
| Lipoic Acid | 58.6 |
| Placebo | 37.5 |
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of IgE in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: 60 days
| Intervention | pg/mL (Mean) |
|---|---|
| Lipoic Acid | 14.53 |
| Placebo | 23.19 |
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of immunoglobulin E (IgE) in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: Baseline
| Intervention | pg/mL (Mean) |
|---|---|
| Lipoic Acid | 37.77 |
| Placebo | 39.90 |
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 13.65 |
| Placebo | 14.46 |
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: 60 days
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 19.13 |
| Placebo | 17.71 |
"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 3.86 |
| Placebo | 3.72 |
"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: 60 days
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 5.57 |
| Placebo | 5.10 |
Measurement of spirometric parameters at baseline: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters/sec (Mean) |
|---|---|
| Lipoic Acid | 4.89 |
| Placebo | 6.09 |
Measurement of spirometric FEF after 60 days of treatment: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters/sec (Mean) |
|---|---|
| Lipoic Acid | 5.47 |
| Placebo | 6.10 |
Measurement of spirometric predicted parameters at baseline: Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.01 |
| Placebo | 2.37 |
Measurement of spirometric predicted parameters after 60 days of treatment. Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.26 |
| Placebo | 2.35 |
Measurement of spirometric predicted parameters at baseline. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.74 |
| Placebo | 3.07 |
Measurement of spirometric predicted parameters at the baseline and after 60 days of treatment: Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.82 |
| Placebo | 3.06 |
18 reviews available for thioctic acid and Diabetes Mellitus
| Article | Year |
|---|---|
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review.
Topics: Administration, Oral; Databases, Factual; Diabetes Mellitus; Diabetic Neuropathies; Humans; Lower Ex | 2023 |
The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials.
Topics: Antioxidants; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Dietary Supplements; | 2021 |
The role of biofactors in the prevention and treatment of age-related diseases.
Topics: Aged; Cardiovascular Diseases; Dementia; Diabetes Mellitus; Dietary Fiber; Dietary Supplements; Epig | 2021 |
Potential Glioprotective Strategies Against Diabetes-Induced Brain Toxicity.
Topics: Animals; Astrocytes; Brain; Diabetes Mellitus; Glucose; Humans; Isoflavones; Oxidative Stress; React | 2021 |
[Advances in the studies of lipoic acid in male infertility].
Topics: Animals; Antioxidants; Asthenozoospermia; Diabetes Mellitus; Erectile Dysfunction; Humans; Infertili | 2017 |
Efficacy of α-lipoic acid in diabetic neuropathy.
Topics: Antioxidants; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropat | 2014 |
Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes.
Topics: Animals; Antioxidants; Diabetes Mellitus; Humans; Mitochondria; Oxidative Stress; Reactive Nitrogen | 2015 |
[An endogenous dithiol with antioxidant properties: alpha-lipoic acid, potential uses in cardiovascular diseases].
Topics: 8,11,14-Eicosatrienoic Acid; Animal Experimentation; Animals; Antioxidants; Cardiovascular Diseases; | 2008 |
Alpha-lipoic acid supplementation and diabetes.
Topics: Aging; Animals; Antioxidants; Biological Availability; Diabetes Mellitus; Diabetic Neuropathies; Die | 2008 |
Antioxidant therapy in human endocrine disorders.
Topics: Antioxidants; Ascorbic Acid; Diabetes Mellitus; Female; Humans; Infertility; Male; Oxidative Stress; | 2010 |
Antioxidants in the treatment of diabetes.
Topics: Antioxidants; Ascorbic Acid; Carnitine; Clinical Trials as Topic; Diabetes Complications; Diabetes M | 2011 |
Direct and indirect antioxidant properties of α-lipoic acid and therapeutic potential.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Chelating Agents; Diabetes Mellitus; Dietary Supplem | 2013 |
Exercise training and antioxidants: relief from oxidative stress and insulin resistance.
Topics: Diabetes Mellitus; Exercise; Glucose; Homeostasis; Humans; Insulin Resistance; Models, Animal; Molec | 2003 |
[Pathogenesis and progression of neuropathies in diabetic patients with endothelial dysfunction].
Topics: Aldehyde Reductase; Animals; Antioxidants; C-Peptide; Diabetes Mellitus; Diabetic Neuropathies; Dise | 2005 |
Natural therapies for ocular disorders, part two: cataracts and glaucoma.
Topics: Cataract; Diabetes Complications; Diabetes Mellitus; Female; Glaucoma; Glucose; Glutathione; Humans; | 2001 |
Use of antioxidant nutrients in the prevention and treatment of type 2 diabetes.
Topics: Antioxidants; Blood Glucose; Cardiovascular Diseases; Developed Countries; Diabetes Complications; D | 2001 |
Molecular aspects of lipoic acid in the prevention of diabetes complications.
Topics: Antioxidants; Biological Availability; Cataract; Diabetes Complications; Diabetes Mellitus; Diabetic | 2001 |
[Clinical use of thioctic acid].
Topics: Animals; Brain Chemistry; Diabetes Mellitus; Diuretics; Glycogen; Hepatolenticular Degeneration; Hum | 1969 |
5 trials available for thioctic acid and Diabetes Mellitus
| Article | Year |
|---|---|
Alpha-lipoic acid improved anemia, erythropoietin resistance, maintained glycemic control, and reduced cardiovascular risk in diabetic patients on hemodialysis: a multi-center prospective randomized controlled study.
Topics: Anemia; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Erythropoietin; Fructosamine | 2022 |
Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Dia | 2022 |
The 8-Week Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) as an Add-on Therapy in the Treatment of Symptomatic Diabetic Peripheral Polyneuropathy.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Neuralgia; Polyneuropathies; Quality of Life; Sing | 2022 |
[Comparative study of alpha-lipoic acid and mexidol effects on affective status, cognitive functions and quality of life in diabetes mellitus patients].
Topics: Antioxidants; Attention; Cognition; Cognition Disorders; Diabetes Complications; Diabetes Mellitus; | 2011 |
[Complex evaluation of treatment efficacy in diabetic encephalopathy].
Topics: Adult; Brain Diseases, Metabolic; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; M | 2002 |
36 other studies available for thioctic acid and Diabetes Mellitus
| Article | Year |
|---|---|
[Diabetic encephalopathy: current insights and potential therapeutic strategies].
Topics: Antioxidants; Brain Diseases; Diabetes Mellitus; Diabetic Neuropathies; Humans; Polyneuropathies; Th | 2021 |
Injectable and self-healing chitosan-based hydrogel with MOF-loaded α-lipoic acid promotes diabetic wound healing.
Topics: Animals; Chitosan; Diabetes Mellitus; Humans; Hydrogels; Rats; Rats, Sprague-Dawley; Thioctic Acid; | 2021 |
[Insulin autoimmune syndrome induced by alpha-lipoic acid in two diabetic patients and HLA-DRB1 alleles analysis in first-degree family members].
Topics: Alleles; Diabetes Mellitus; Family; HLA-DRB1 Chains; Humans; Insulins; Thioctic Acid | 2020 |
Exploring the effectiveness of vitamin B
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Inflammation; Meta-Analysis as Topic; Randomized C | 2022 |
Alpha-lipoic acid activates AMPK to protect against oxidative stress and apoptosis in rats with diabetic peripheral neuropathy.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Diabetes Mellitus; Diabetic Neuropathies; NF-E2-R | 2023 |
A Pilot Study Suggesting Several Benefits of Alpha Lipoic Acid in Patients with Diabetes.
Topics: Antioxidants; Diabetes Mellitus; Humans; Pilot Projects; Thioctic Acid | 2023 |
Morbidity and mortality of patients with diabetic neuropathy treated with pathogenetically oriented alpha-lipoic acid versus symptomatic pharmacotherapies - A nationwide database analysis from Hungary.
Topics: Antioxidants; Diabetes Mellitus; Diabetic Neuropathies; Humans; Hungary; Retrospective Studies; Thio | 2023 |
To Study the Eff ect of Alpha Lipoic Acid Supplementation on Diabetic Neuropathy through Nerve Conduction Test.
Topics: Antioxidants; Diabetes Mellitus; Diabetic Neuropathies; Dietary Supplements; Humans; Neural Conducti | 2020 |
Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection.
Topics: ADAM17 Protein; Angiotensin-Converting Enzyme 2; Antioxidants; Betacoronavirus; Coronavirus Infectio | 2020 |
Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.
Topics: Adult; Antioxidants; Body Mass Index; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Insulin | 2018 |
Regulation of Vascular Tone, Angiogenesis and Cellular Bioenergetics by the 3-Mercaptopyruvate Sulfurtransferase/H2S Pathway: Functional Impairment by Hyperglycemia and Restoration by DL-α-Lipoic Acid.
Topics: Animals; Cell Line; Cyclic GMP-Dependent Protein Kinases; Cysteine; Diabetes Mellitus; Disease Model | 2015 |
Nε-(carboxymethyl) lysine-induced mitochondrial fission and mitophagy cause decreased insulin secretion from β-cells.
Topics: Animals; Antioxidants; Biomarkers; Cell Line, Tumor; Diabetes Mellitus; Dietary Supplements; Down-Re | 2015 |
Oxidative stress increases the risk of pancreatic β cell damage in chronic renal hypertensive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti | 2016 |
ROS-mediated lipopolysaccharide-induced apoptosis in INS-1 cells by modulation of Bcl-2 and Bax.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Diabetes Mellitus; Insulin-Secreti | 2012 |
α-lipoic acid inhibits high glucose-induced apoptosis in HIT-T15 cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Cell Line; Cell Prolif | 2012 |
Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid.
Topics: Albuminuria; Animals; Antioxidants; Blood Glucose; Body Weight; Diabetes Mellitus; F2-Isoprostanes; | 2003 |
A screening investigation of the use of lipoic acid as an anti-diabetic agent.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Thioctic Acid | 1961 |
[On the treatment of diabetic neuropathy].
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Neurologic Manifestations; Thioctic Acid | 1961 |
[Treatment of polyneuritic complications in diabetes with thioctic acid].
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Neuritis; Thioctic Acid | 1963 |
Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice.
Topics: Acetylcholine; Aldehyde Reductase; Animals; Antioxidants; Biomarkers; Diabetes Mellitus; Dinoprost; | 2006 |
Diabetes--a man made disease.
Topics: Antioxidants; Ascorbic Acid; Diabetes Mellitus; Environment; Food Handling; Glycation End Products, | 2006 |
An overdose of alpha lipoic acid may cause trace element deficiency in diabetes mellitus.
Topics: Antioxidants; Chelating Agents; Diabetes Mellitus; Drug Overdose; Humans; Models, Biological; Thioct | 2006 |
Effects of lipoic acid and dihydrolipoic acid on total erythrocytic thiols under conditions of restricted glucose in vitro.
Topics: Adult; Cells, Cultured; Diabetes Mellitus; Erythrocytes; Humans; Hypoglycemia; Methemoglobin; Sulfhy | 2007 |
Maturity-onset diabetes mellitus--toward a physiological appropriate management.
Topics: Amino Acids; Aspirin; Carnitine; Chromium; Diabetes Mellitus; Dietary Fats; Dietary Fiber; Fasting; | 1981 |
Rationales for micronutrient supplementation in diabetes.
Topics: Animals; Antioxidants; Ascorbic Acid; Calcium; Carnitine; Chromium; Diabetes Mellitus; gamma-Linolen | 1984 |
Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging.
Topics: Adult; Aged; Aging; Antibodies; Arteries; Arteriosclerosis; Biomarkers; Blood Proteins; Catalase; Ch | 1997 |
The antioxidant properties of thioctic acid: characterization by cyclic voltammetry.
Topics: Adult; Aged; Antioxidants; Diabetes Mellitus; Electrochemistry; Female; Heparin; Humans; Male; Middl | 1997 |
alpha-Lipoic acid.
Topics: Antioxidants; Diabetes Mellitus; Humans; Thioctic Acid | 1998 |
Modelling cortical cataractogenesis XX. In vitro effect of alpha-lipoic acid on glutathione concentrations in lens in model diabetic cataractogenesis.
Topics: Animals; Cataract; Culture Techniques; Diabetes Complications; Diabetes Mellitus; Disease Models, An | 1998 |
alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; Glucose Tolerance Test; Glycat | 1999 |
Influence of diabetes on cardiac nitric oxide synthase expression and activity.
Topics: Animals; Antioxidants; Blotting, Western; Collagenases; Diabetes Mellitus; Endothelium; Gene Express | 2000 |
Lipoate prevents glucose-induced protein modifications.
Topics: Diabetes Mellitus; Glucose; Glycosylation; Humans; Muramidase; Serum Albumin, Bovine; Thioctic Acid | 1992 |
[Use of lipoic acid in diabetes mellitus].
Topics: Diabetes Mellitus; Humans; Liver; Thioctic Acid | 1972 |
[Lipoic (thioctic) acid and its significance in hepatology].
Topics: Animals; Arrhythmias, Cardiac; Arteriosclerosis; Carbohydrate Metabolism; Diabetes Mellitus; Humans; | 1969 |
[Diabetic neuropathy].
Topics: Aged; Diabetes Mellitus; Diabetic Neuropathies; Humans; Middle Aged; Thiamine; Thioctic Acid | 1969 |
[What is reliable in the therapy of diabetes mellitus?].
Topics: Carbutamide; Chlorpropamide; Chronic Disease; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nep | 1970 |